The Hidden Cost of AI Hallucinations in Critical Document Creation

It's 11 PM on a Friday. Your regulatory affairs lead just opened an email from the FDA—a Complete Response letter for your CTD submission. Somewhere in those 10,000 pages, there's a citation to a clinical trial that doesn't exist. The AI that drafted Section 2.7 invented it. Now your team is pulling up the master file, scanning every reference, trying to figure out which ones are real and which are fabrications. The patent clock keeps ticking. Your competitor's application is still on track. And 50,000 patients waiting for your cancer treatment just got pushed back another six months.

This scenario isn't hypothetical. In late 2025, two major government healthcare reports were found to contain AI-generated fabrications—fake academic citations, invented court quotes, non-existent studies^1,2. If it can happen to well-resourced consulting firms with layers of review, it can happen to your regulatory submission.

What a Hallucination Actually Looks Like

The most dangerous hallucinations aren't the obvious ones. They're the citations that almost exist. Here's what your AI might generate:

The trial number follows the correct format. The investigator name sounds plausible. The statistics are reasonable. But NCT04829123 doesn't exist—the AI synthesized it from patterns in its training data. A reviewer scanning quickly might miss it. An FDA examiner won't.

The Cascade Nobody Talks About

Here's what happens when that fabricated reference slips through:

Your submission enters a "complete response" cycle—regulatory speak for "start over." Each day of delay costs millions³. For a drug with $2 billion in projected annual sales, a six-month delay doesn't just mean lost revenue. It means competitors capturing market share. It means physicians establishing prescribing habits with alternative treatments. It means 50,000 patients who needed your drug six months ago are still waiting—or worse, have progressed beyond the point where it could help.

The Uncomfortable Truth About Why AI Lies

Here's something most vendors won't tell you: AI doesn't hallucinate because it's broken. It hallucinates because that's exactly what researchers trained it to do.

OpenAI's own 2025 research⁴ explains it bluntly: standard training procedures reward guessing over admitting uncertainty. When an AI says "I don't know," it gets penalized. When it confidently generates a plausible-sounding answer—even a wrong one—it gets rewarded. The result? Systems that would rather fabricate a clinical trial reference than leave a blank.

In medical and pharmaceutical content, this creates a perfect storm. Top AI models hallucinate 0.7%-16.9% of the time⁵. That's roughly once every 6 to 140 statements. In a 200-page regulatory section, you're looking at dozens of potential fabrications waiting to torpedo your submission.

Notice something counterintuitive in that chart? General content has the lowest hallucination rates. The more specialized your domain—legal, medical, pharmaceutical—the more likely the AI is to make things up. Why? Because regulatory language uses precise terminology that rarely appears in training data. The AI has less to work with, so it improvises. Confidently. Incorrectly.

The Paradox You Can't Escape

So we should just avoid AI entirely, right? Here's the problem: you can't.

A CTD submission can span 10,000+ pages across all modules. Manual drafting takes months of work from multiple regulatory affairs specialists. Your competitors are already using AI. The FDA itself has recognized this reality—their January 2025 guidance⁶ explicitly acknowledges that AI will play a "critical role in the drug development life cycle."

The agency isn't warning companies away from AI. They're building frameworks for how to use it responsibly. That's a crucial distinction.

Three Things That Actually Work

The FDA's January 2025 framework⁷ isn't just bureaucratic checkbox exercise. It reflects hard lessons from companies that got this right—and wrong. Here's what separates them:

1. Ground Your AI in Reality

The technical term is "Retrieval Augmented Generation" (RAG), but here's what it actually means: instead of letting your AI generate answers from its training data (where hallucinations live), you connect it directly to verified databases—FDA regulations, ICH guidelines, your own validated trial data. Every claim the AI makes must trace back to a real source.

Think of it as the difference between asking someone to write a report from memory versus giving them access to the original documents. The AI becomes a sophisticated search-and-synthesis tool rather than a confident fabricator.

2. Build a Three-Question Litmus Test

Before any AI-generated content enters a critical document, your team should ask three questions:

• Can I find this source independently? If the AI cites NCT04829123, can you locate it in ClinicalTrials.gov?
• Does this claim match my domain expertise? If a statistic feels too convenient, it probably is.
• Would I stake my signature on this? The FDA holds people accountable, not algorithms.

This isn't about adding bureaucracy. It's about catching the 4.3% of medical content that AI gets wrong before it derails a $50 million submission.

3. Treat AI Validation Like Clinical Data Validation

Your organization already has rigorous processes for validating clinical trial data. AI outputs deserve the same scrutiny. Version control. Audit trails. Source documentation. If you can't trace an AI-generated statement back to its origin, it doesn't belong in your submission.

The Decision You're Already Making

Here's what I've learned from watching this space: the organizations that succeed with AI in regulatory submissions aren't the ones with the most sophisticated technology. They're the ones that treat AI like a brilliant but unreliable colleague—someone who can synthesize vast amounts of information quickly, but whose work you always verify before it goes out the door.

Your next CTD submission will use AI. That decision has already been made for you by the market, by your competitors, and by the FDA itself. The only question left: Will you be the team that catches the fabricated NCT number at 3 PM on a Tuesday, or the one explaining a Complete Response letter to your board on a Friday night?

The technology is ready. The frameworks exist. The only variable is how seriously your organization takes the gap between what AI promises and what it actually delivers.

At Ritivel, we're tackling this problem by questioning everything our AI generates—building verification into every step of the process rather than bolting it on at the end. More on how we're doing this in an upcoming post.

References